✦ LIBER ✦

VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma

✍ Scribed by Pineda-Roman, M; Zangari, M; van Rhee, F; Anaissie, E; Szymonifka, J; Hoering, A; Petty, N; Crowley, J; Shaughnessy, J; Epstein, J

Book ID: 109886843
Publisher: Nature Publishing Group
Year: 2008
Tongue: English
Weight: 279 KB
Volume: 22
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2008.99

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bortezomib in combination with thalidomi

Bortezomib in combination with thalidomide and dexamethasone—a successful treatment regimen in refractory extramedullary multiple myeloma

✍ Dominik Dytfeld; Magdalena Matuszak; Krzysztof Lewandowski; Mieczysław Komarnick 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 84 KB

The oral combination of thalidomide, cyc

The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma

✍ García-Sanz, R; González-Porras, J R; Hernández, J M; Polo-Zarzuela, M; Sureda, 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 169 KB

Clarithromycin with low dose dexamethaso

Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma

✍ T. C. M. Morris; P. J. Kettle; M. Drake; F. C. G. Jones; D. R. Hull; K. Boyd; A. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

Bortezomib in combination with epirubici

Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience

✍ Shuqing Lü; Jianmin Wang; Xiaoqian Xu; Xiong Ni; Chongmei Huang; Huiying Qiu; Xi 📂 Article 📅 2008 🏛 Carden Jennings Publishing 🌐 English ⚖ 158 KB

Combined pegylated liposomal doxorubicin

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

✍ Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan Bladé; Tadeusz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). I

Rapid complete remission in multiple mye

Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome

✍ C. S. Chim 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 163 KB